Cite this article
Volume | Year
European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Laparoendoscopic single-site surgery for the assessment of peritoneal carcinomatosis resectability in patients with advanced ovarian cancer
D. Rossetti1, S.G. Vitale2,*, F.A. Gulino2, A.M.C. Rapisarda2, G. Valenti2, M. Zigarelli2, G. Sarpietro2, L. Frigerio1
1 Department of Obstetrics and Gynecology, "Papa Giovanni XXIII" Hospital, Bergamo, Italy
2 Department of General Surgery and Medical Surgical Specialties, University of Catania, Catania, Italy
Eur. J. Gynaecol. Oncol. 2016, 37(5), 671–673; https://doi.org/10.12892/ejgo3234.2016
Published: 10 October 2016
Purpose of investigation: To evaluate the feasibility, safety, and effectiveness of laparoendoscopic single site surgery (LESS) for the assessment of peritoneal carcinomatosis resectability in patients with advanced stage ovarian cancer (AOC). Materials and Methods: The authors retrospectively reviewed the medical records of patients affected by advanced stage ovarian cancer who underwent LESS for operative work-up. A standard cytoreductive laparotomy surgery (CRS) was performed. Results: Fifty-two women affected by AOC underwent LESS for operative work-up. The peritoneal cancer score was completed in 49 (94%) patients by use of LESS; 34/37 (92%) patients considered with a resectable disease were effectively optimally debulked and 15/52 (28%) patients considered with an unresectable disease received before neoadjuvant chemotherapy (NACT) and then underwent surgery. Conclusion: LESS is feasible, safe, and is an alternative minimally invasive procedure to assess the resectability of AOC patients.
Laparoendoscopic single-site surgery (LESS)
Advanced epithelial ovarian cancer